Audiência alta. Cidade cheia. Lore viva.
#COMPREXO não só inaugurou mais dominou o RedM.

Parabéns toda equipe do #CPRX

Acesse: linktr.ee/OCOROAgg

#CPRX Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CPRX/catalyst-pharm...

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on

#CPRX UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

www.stocktitan.net/news/CPRX/updated-cataly...

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals Catalyst Pharmaceuticals (NASDAQ:CPRX) has announced a settlement agreement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE® (amifampridine). Under the agreement, Lupin receives a license to market a generic version of FIRDAPSE starting February 25, 2035, pending FDA approval.The settlement resolves the patent litigation initiated by Catalyst and SERB S.A. in response to Lupin's Abbreviated New Drug Application (ANDA). All ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey will be terminated. This follows similar settlements with Teva Pharmaceuticals and Inventia Life Science, while litigation against Hetero remains ongoing.

#CPRX Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

www.stocktitan.net/news/CPRX/catalyst-pharm...

90% of SCLC Patients Miss LEMS Diagnosis: NCCN Updates Guidelines with Critical Testing Protocol NCCN adds VGCC antibody testing and amifampridine treatment recommendations for LEMS in SCLC patients. New guidelines target improved diagnosis rates. Learn more.

#CPRX Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

www.stocktitan.net/news/CPRX/lambert-eaton-...

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update Catalyst Pharmaceuticals (CPRX) reported exceptional Q1 2025 financial results with total revenues reaching $141.4 million, representing a 43.6% year-over-year increase. The company's portfolio showed strong performance across all products: FIRDAPSE revenue grew 25.3% to $83.7M, AGAMREE generated $22.0M, and FYCOMPA contributed $35.6M (+17.1% YoY). GAAP net income surged 143.8% to $56.7M. The company maintains a robust financial position with $580.7M in cash and no debt. Catalyst reaffirmed its full-year 2025 revenue guidance of $545-565M, demonstrating confidence in continued growth. Key developments include Health Canada's acceptance of AGAMREE's New Drug Submission and a settlement with Teva regarding FIRDAPSE patent litigation, securing market exclusivity until February 2035.

#CPRX Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CPRX/catalyst-pharm...

First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status Health Canada fast-tracks novel DMD therapy review, positioning AGAMREE to become Canada's first approved treatment. Recent US launch strengthens outlook.

#CPRX Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

www.stocktitan.net/news/CPRX/catalyst-pharm...

Breakthrough: First-Ever DMD Treatment AGAMREE Fast-Tracked in Canada Health Canada expedites review of AGAMREE, potentially bringing the first approved Duchenne muscular dystrophy treatment to 800+ Canadian patients. Full analysis inside.

#CPRX New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

www.stocktitan.net/news/CPRX/new-drug-submi...

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Catalyst Pharmaceuticals (CPRX) reported strong financial results for Q4 and full year 2024, with total revenues reaching $491.7 million, marking a 23.5% year-over-year growth. The company's portfolio performance was driven by three key products: FIRDAPSE® ($306.0M), AGAMREE® ($46.0M), and FYCOMPA® ($137.3M).Q4 2024 revenues were $141.8 million, up 28.3% YoY, with GAAP net income of $55.9 million. The company projects 2025 total revenues between $545-565 million, with FIRDAPSE expected to generate $355-360M, AGAMREE $100-110M, and FYCOMPA $90-95M.Notable achievements include AGAMREE's successful US launch, FIRDAPSE's FDA-approved dose increase, and a settlement agreement with Teva regarding patent litigation. The company ended 2024 with $517.6 million in cash and cash equivalents.

#CPRX Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/CPRX/catalyst-pharm...

Catalyst Pharmaceuticals Expands Global Reach: FIRDAPSE LEMS Treatment Launches in Japan Catalyst's rare disease drug FIRDAPSE enters Japanese market through DyDo Pharma, expanding access to the only FDA-approved LEMS treatment for muscle weakness.

#CPRX Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

www.stocktitan.net/news/CPRX/catalyst-pharm...

News; ( NASDAQ: #CPRX ) Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Teva Pharmaceuticals

Catalyst Pharma Secures FIRDAPSE Patent Protection Against Teva Until 2035 in Settlement Win Catalyst Pharmaceuticals reaches settlement with Teva, blocking generic FIRDAPSE competition until 2035. Patent litigation continues against Hetero and Lupin.

#CPRX Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

www.stocktitan.net/news/CPRX/catalyst-pharm...

#CPRX Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

www.stocktitan.net/news/CPRX/catalyst-pharm...

Breaking News: ( NASDAQ: #CPRX ) Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

#StockMarket #News